Molecular therapies for viral hepatitis

BioDrugs

Volumn 17, Issue 2, 2003, Pages 81-91

  Guha, Chandan ^a   Shah, Shalin J ^a   Ghosh, Siddhartha S ^a   Lee, Sung W ^a   Roy Chowdhury, Namita ^a   Roy Chowdhury, Jayanta ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ALPHA2 INTERFERON; COMPLEMENTARY RNA; DNA VACCINE; GLYCOPROTEIN E; GLYCOPROTEIN E2; HEPATITIS B VACCINE; LAMIVUDINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MEMBRANE PROTEIN; PEGINTERFERON ALPHA2A; PLASMID DNA; RIBAVIRIN; RIBOZYME; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG RESEARCH; DRUG SCREENING; GENE THERAPY; GENE TRANSFER; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; VIRUS HEPATITIS; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; GENE THERAPY; HEPATITIS B; HEPATITIS C; HUMANS; VACCINES, DNA; VIRAL HEPATITIS VACCINES;

EID: 0037258795     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317020-00001     Document Type: Review

References (84)

1. Ruiz J, Qian C, Drozdzik M, et al. Gene therapy of viral hepatitis and hepatocellular carcinoma. J Viral Hepat 1999; 6: 17-34
2. von Weizsacker F, Wieland S, Kock J, et al. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology 1997; 26: 251-5
3. Wands JR, Geissler M, Putlitz JZ, et al. Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection. J Gastroenterol Hepatol 1997; 12: S354-69
4. Manoharan M. 2′-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim Biophys Acta 1999; 1489: 117-30
5. Gryaznov SM. Oligonucleotide N3′→P5′ phosphoramidates as potential therapeutic agents. Biochim Biophys Acta 1999; 1489: 131-40
6. Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999; 1489: 69-84
7. Wu J, Gerber MA. The inhibitory effects of antisense RNA on hepatitis B virus surface antigen synthesis. J Gen Virol 1997; 78: 641-7
8. Kren BT, Parashar B, Bandyopadhyay P, et al. Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type 1 with a chimeric oligonucleotide. Proc Natl Acad Sci U S A 1999; 96: 10349-54
9. Kren BT, Bandyopadhyay P, Chowdhury NR, et al. Oligonucleotide-mediated site-directed gene repair. Methods Enzymol 2002; 346: 14-35
10. zu Putlitz J, Wieland S, Blum HE, et al. Antisense RNA complementary to hepatitis B virus specifically inhibits viral replication. Gastroenterology 1998; 115: 702-13
11. Chisari FV. Rous-Whipple Award Lecture: viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000; 156: 1117-32
12. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312-23
13. Yuen MF, Lai CL. Treatment of chronic hepatitis B. Lancet Infect Dis 2001; 1: 232-41
14. Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B: an Italian multicenter, randomized trial. J Hepatol 2001; 35: 406-11
15. Wu GY, Wu CH. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J Biol Chem 1992; 267: 12436-9
16. Robaczewska M, Guerret S, Remy JS, et al. Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver. Gene Ther 2001; 8: 874-81
17. zu Putlitz J, Yu Q, Burke JM, et al. Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus. J Virol 1999; 73: 5381-7
18. Welch PJ, Tritz R, Yei S, et al. Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther 1997; 4: 736-43
19. Scaglioni PP, Melegari M, Wands JR. Characterization of hepatitis B virus core mutants that inhibit viral replication. Virology 1994; 205: 112-20
20. Scaglioni P, Melegari M, Takahashi M, et al. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 1996; 24: 1010-7
21. Di Bisceglie AM, McHutchison J, Rice CM. New therapeutic strategies for hepatitis C. Hepatology 2002; 35: 224-31
22. Drazan KE. Molecular biology of hepatitis C infection. Liver Transpl 2000; 6: 396-406
23. McHutchison JG. Hepatitis C advances in antiviral therapy: what is accepted treatment now? J Gastroenterol Hepatol 2002; 17: 431-41
24. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65
25. Wakita T, Wands JR. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides: in vitro model for selection of target sequence. J Biol Chem 1994; 269: 14205-10
26. Wakita T, Moradpour D, Tokushihge K, et al. Antiviral effects of antisense RNA on hepatitis C virus RNA translation and expression. J Med Virol 1999; 57: 217-22
27. Welch PJ, Tritz R, Yei S, et al. A potential therapeutic application of hairpin ribozymes: in vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther 1996; 3: 994-1001
28. Welch PJ, Yei S, Barber JR. Ribozyme gene therapy for hepatitis C virus infection. Clin Diagn Virol 1998; 10: 163-71
29. Sakamoto N, Wu CH, Wu GY. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 1996; 98: 2720-8
30. Macejak DG, Jensen KL, Jamison SF, et al. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology 2000; 31: 769-76
31. Macejak DG, Jensen KL, Pavco PA, et al. Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA. J Viral Hepat 2001; 8: 400-5
32. Lieber A, He CY, Polyak SJ, et al. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 1996; 70: 8782-91
33. Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36
34. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-9
35. Zuckerman AJ. Prevention of primary liver cancer by immunization. N Engl J Med 1997; 336: 1906-7
36. Michel ML, Pol S, Brechot C, et al. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 2001; 19: 2395-9
37. Fuller JT, Fuller DH, McCabe D, et al. Immune responses to hepatitis B virus surface and core antigens in mice, monkeys, and pigs after Accell particle-mediated DNA immunization. Ann N Y Acad Sci 1995; 772: 282-4
38. Loirat D, Lemonnier FA, Michel ML. Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization. J Immunol 2000; 165: 4748-55
39. Michel ML, Loirat D. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B. Intervirology 2001; 44: 78-87
40. Schirmbeck R, Bohm W, Ando K, et al. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol 1995; 69: 5929-34
41. Ishioka GY, Fikes J, Hermanson G, et al. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 1999; 162: 3915-25
42. Le Borgne S, Mancini M, Le Grand R, et al. In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen. Virology 1998; 240: 304-15
43. Geissler M, Tokushige K, Wakita T, et al. Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs. Vaccine 1998; 16: 857-67
44. Major ME, Vitvitski L, Mink MA, et al. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol 1995; 69: 5798-805
45. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157: 1840-5
46. Klinman DM, Yi AK, Beaucage SL, et al. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 1996; 93: 2879-83
47. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000; 18: 927-74
48. Akbari O, Panjwani N, Garcia S, et al. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 1999; 189: 169-78
49. Sallberg M, Townsend K, Chen M, et al. Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens. J Virol 1997; 71: 5295-303
50. Shiraki K, Hayakawa Y, Mori H, et al. Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen. J Gen Virol 1991; 72: 1393-9
51. Kondo R, Feitelson MA, Strayer DS. Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent. Gene Ther 1998; 5: 575-82
52. Prange R, Werr M. DNA-mediated immunization to hepatitis B virus envelope proteins: preS antigen secretion enhances the humoral response. Vaccine 1999; 17: 617-23
53. Hsu HH, Abrignani S, Houghton M. Prospects for a hepatitis C virus vaccine. Clin Liver Dis 1999; 3: 901-15
54. Lechmann M, Liang TJ. Vaccine development for hepatitis C. Semin Liver Dis 2000; 20: 211-26
55. Heile JM, Fong YL, Rosa D, et al. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. J Virol 2000; 74: 6885-92
56. Zucchelli S, Capone S, Fattori E, et al. Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol 2000; 74: 11598-607
57. Forns X, Payette PJ, Ma X, et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 2000; 32: 618-25
58. Bukh J, Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci U S A 1994; 91: 8239-43
59. Christie JM, Chapel H, Chapman RW, et al. Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. Hepatology 1999; 30: 1037-44
60. Tokushige K, Wakita T, Pachuk C, et al. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatology 1996; 24: 14-20
61. McLauchlan J. Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J Viral Hepat 2000; 7: 2-14
62. Polakos NK, Drane D, Cox J, et al. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol 2001; 166: 3589-98
63. Encke J, zu Putlitz J, Geissler M, et al. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 1998; 161: 4917-23
64. Brinster C, Muguet S, Lone YC, et al. Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA- expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology 2001; 34: 1206-17
65. Wedemeyer H, Gagneten S, Davis A, et al. Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV- specific CTL in a transgenic mouse model. Gastroenterology 2001; 121: 1158-66
66. Satoi J, Murata K, Lechmann M, et al. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins. J Virol 2001; 75: 12121-7
67. Nemchinov LG, Liang TJ, Rifaat MM, et al. Development of a plant-derived subunit vaccine candidate against hepatitis C virus. Arch Virol 2000; 145: 2557-73
68. Bartholomew RM, Carmichael EP, Findeis MA, et al. Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks. J Viral Hepat 1995; 2: 273-8
69. Smith RM, Wu GY. Hepatocyte-directed gene delivery by receptor-mediated endocytosis. Semin Liver Dis 1999; 19: 83-92
70. Ivics Z, Hackett PB, Plasterk RH, et al. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997; 91: 501-10
71. Yant SR, Meuse L, Chiu W, et al. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000; 25: 35-41
72. Tung FYT, Bowen SW. Targeted inhibition of hepatitis B virus gene expression: a gene therapy approach. Front Biosci 1998; 3: a11-5
73. Kalpana GV. Retroviral vectors for liver-directed gene therapy. Semin Liver Dis 1999; 19: 27-37
74. Wang L, Takabe K, Bidlingmaier SM, et al. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci U S A 1999; 96: 3906-10
75. Strayer DS. SV40-based gene therapy vectors: turning an adversary into a friend. Curr Opin Mol Ther 2000; 2: 570-8
76. Strayer DS, Zern MA. Gene delivery to the liver using simian virus 40-derived vectors. Semin Liver Dis 1999; 19: 71-81
77. Ilan Y, Saito H, Thummala NR, et al. Adenovirus-mediated gene therapy of liver diseases. Semin Liver Dis 1999; 19: 49-59
78. Chirmule N, Hughes JV, Gao GP, et al. Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J Virol 1998; 72: 6138-45
79. Kafri T, Morgan D, Krahl T, et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci U S A 1998; 95: 11377-82
80. Thummala NR, Ghosh SS, Lee SW, et al. A non-immunogenic adenoviral vector, coexpressing CTLA4Ig and bilirubin-uridine-diphosphoglucuronateglucuronosyltransferase permits long-term, repeatable transgene expression in the Gunn rat model of Crigler-Najjar syndrome. Gene Ther 2002; 9: 981-90
81. Feng M, Jackson Jr WH, Goldman CK, et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol 1997; 15: 866-70
82. Recchia A, Parks RJ, Lamartina S, et al. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci U S A 1999; 96: 2615-20
83. Calos MP. The potential of extrachromosomal replicating vectors for gene therapy. Trends Genet 1996; 12: 463-6
84. Leblois L, Roche C, Di Falco ND, et al. Stable transduction of actively dividing cells via a novel adenoviral/episomal vector. Mol Ther 2000; 1: 314-22